{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"description":"Number of patients expired without disease progression/relapse.","groups":[{"description":"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.\n\nIMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo allogeneic peripheral blood stem cell transplant\n\nSirolimus: Given PO\n\nTotal-Body Irradiation: Undergo total-body irradiation","id":"OG000","title":"Treatment (Fludarabine, Transplant, Immunosuppression)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One subject aborted transplant during conditioning and was counted towards accrual but not evaluated with respect to outcome measures.","reportingStatus":"POSTED","timeFrame":"100 days post-transplant","title":"Number of Non-Relapse Mortalities","type":"SECONDARY","unitOfMeasure":"Participants"}